| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
EGTA-AM targets intracellular calcium ions (Ca²⁺). As a membrane-permeable acetoxymethyl ester, it enters cells where it is hydrolyzed by intracellular esterases to release EGTA, a high-affinity Ca²⁺ chelator. EGTA then binds to free Ca²⁺ ions, buffering intracellular calcium levels and modulating calcium-dependent cellular processes.
|
|---|---|
| ln Vitro |
Only synchronous excitatory postsynaptic currents (EPSCs) are reduced by EGTA-AM (50 μM) to measure train-generated charge transfer; asynchronous EPSCs are significantly reduced to 58.9 ± 8.1% of control levels [1].
In vitro, EGTA-AM is used as a tool to chelate intracellular calcium ions in cell-based assays. By buffering intracellular Ca²⁺, it allows researchers to study the role of calcium in various cellular functions, including signal transduction, muscle contraction, and neurotransmitter release. |
| ln Vivo |
In vivo activity data for EGTA-AM are limited, as it is primarily used as a research tool for in vitro cellular studies. Its membrane-permeable properties allow it to be used in cell loading experiments, but its application in vivo is limited due to its rapid hydrolysis and metabolism.
|
| Enzyme Assay |
In vitro enzyme assays are not typically performed for EGTA-AM, as its mechanism of action is based on calcium chelation rather than enzyme inhibition. However, its ability to chelate calcium can be assessed in cell-free systems by measuring free Ca²⁺ concentrations using calcium-sensitive fluorescent indicators in the presence of the compound.
|
| Cell Assay |
In vitro cellular assays for EGTA-AM are performed using various cell types. Cells are loaded with EGTA-AM by incubation with the compound, which is passively taken up by cells. After loading, intracellular esterases hydrolyze the AM groups to release EGTA. The resulting intracellular calcium buffering is assessed by measuring changes in calcium-dependent cellular processes, such as contraction, secretion, or calcium signaling using fluorescent calcium indicators.
|
| Animal Protocol |
In vivo animal experiments for EGTA-AM are not extensively documented. As a cell-loading reagent, its use is primarily limited to in vitro applications. For in vivo studies, other calcium chelators or methods are typically employed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of EGTA-AM have not been systematically characterized. The compound has a molecular weight of 668.60, molecular formula C26H40N2O18, and a purity of ≥90%. It appears as a neat oil and is soluble in DMSO. It should be stored appropriately to maintain stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for EGTA-AM are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
EGTA-AM is also known as EGTA Acetoxymethyl ester. It is a membrane-permeable form of the EGTA Ca²⁺-chelating agent. It is used in cell biology research to study the role of calcium ions in various cellular processes. This product is for research use only.
|
| Molecular Formula |
C26H40N2O18
|
|---|---|
| Molecular Weight |
668.5984
|
| Exact Mass |
668.228
|
| CAS # |
99590-86-0
|
| PubChem CID |
121907
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.303g/cm3
|
| Boiling Point |
664.2ºC at 760 mmHg
|
| Flash Point |
355.5ºC
|
| Index of Refraction |
1.487
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
33
|
| Heavy Atom Count |
46
|
| Complexity |
857
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(OCOC(C)=O)CN(CC(OCOC(C)=O)=O)CCOCCOCCN(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O
|
| InChi Key |
GNJXVFXIDHCCKR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H40N2O18/c1-19(29)39-15-43-23(33)11-27(12-24(34)44-16-40-20(2)30)5-7-37-9-10-38-8-6-28(13-25(35)45-17-41-21(3)31)14-26(36)46-18-42-22(4)32/h5-18H2,1-4H3
|
| Chemical Name |
acetyloxymethyl 2-[[2-(acetyloxymethoxy)-2-oxoethyl]-[2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]ethoxy]ethoxy]ethyl]amino]acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~149.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4957 mL | 7.4783 mL | 14.9566 mL | |
| 5 mM | 0.2991 mL | 1.4957 mL | 2.9913 mL | |
| 10 mM | 0.1496 mL | 0.7478 mL | 1.4957 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
